Relationship between 24-hour rhythm in antiviral effect of interferon-β and interferon-α/β receptor expression in mice

Japanese Journal of Pharmacology

Volumn 90, Issue 4, 2002, Pages 304-312

  Takane, Hiroshi ^a,b   Ohdo, Shigehiro ^a   Baba, Reiji ^a   Koyanagi, Satoru ^c   Yukawa, Eiji ^a   Higuchi, Shun ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

^c FUKUOKA UNIVERSITY   (Japan)

Author keywords

24 Hour rhythm; Chronopharmacokinetics; Chronopharmacology; Interferon; Interferon receptor

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; ALPHA INTERFERON RECEPTOR; BETA INTERFERON; BETA INTERFERON RECEPTOR; INTERFERON RECEPTOR; MESSENGER RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; CHRONOPHARMACOLOGY; CIRCADIAN RHYTHM; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG POTENCY; ENZYME ACTIVITY; FEVER; FOOD AVAILABILITY; INJECTION; LIGHT; LIGHT DARK CYCLE; LIVER; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; STATISTICAL SIGNIFICANCE; WATER AVAILABILITY;

EID: 0036951592     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.90.304     Document Type: Article

References (41)

1. Burgess HJ, Trinder J, Kim Y and Luke D: Sleep and circadian influences on cardiac autonomic nervous system activity. Am J Physiol 273, H1761 - H1768 (1997)
2. Lévi F, Canon C, Dipalma M, Florentin I and Misset JL: When should the immune clock be reset? From circadian pharmaco-dynamics to temporally optimize drug delivery. Ann NY Acad Sci 618, 312 - 329 (1991)
3. Refinetti R and Menaker M: The circadian rhythm of body temperature. Physiol Behav 51, 613 - 637 (1992)
4. Ohdo S, Koyanagi S, Suyama H, Higuchi S and Aramaki H: Changing the dosing schedule minimizes the disruptive effects of interferon on clock function. Nature Med 7, 356 - 360 (2001)
5. Ohdo S, Koyanagi S, Yukawa E and Higuchi S: Circadian rhythm of fever induced by interferon-α in mice. Life Sci 61, PL95 - PL100 (1997)
6. Ohdo S, Ogawa N, Nakano S and Higuchi S: Influence of feeding schedule on the chronopharmacological aspects of sodium valproate in mice. J Pharmacol Exp Ther 278, 74 - 81 (1996)
7. Hrushesky WJM: Circadian timing of cancer chemotherapy. Science 288, 73 - 75 (1985)
8. Lévi F, Zidani R and Misset JL: Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 350, 681 - 686 (1997)
9. Baron S, Tyring S, Fleischmann WR, Coppenhaver DH, Niesel DW, Klimpel GR, Stanton GJ and Hughes K: The interferons. JAMA 266, 1375 - 1383 (1991)
10. Koyanagi S, Ohdo S, Yukawa E and Higuchi S: Chronopharmacological study of interferon-α in mice. J Pharmacol Exp Ther 283, 259 - 264 (1997)
11. Darnell JE Jr, Kerr IM and Stark GR: Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264, 1415 - 1421 (1994)
12. Novick D, Cohen B and Rubinstein M: The human interferon α/β receptor: Characterization and molecular cloning. Cell 77, 391 - 400 (1994)
13. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC and Perrillo RP: Treatment for chronic hepatitis C with recombinant interferon alpha: A multicenter randomized controlled trial. N Engl J Med 321, 1501 - 1506 (1989)
14. Lin R, Roach R, Zimmerman M, Strasser S and Farrel G: Interferon alpha-2b for chronic hepatitis C: Effect of dose increment and duration of treatment on response rates. J Hepatol 23, 487 - 496 (1995)
15. Toyoda H, Kumada T, Nakano S, Takeda I, Sugiyama K, Osada T, Kiriyama S, Sone Y, Kinoshita M and Hadama T: Quasispecies nature of hepatitis C virus and response to alpha interferon: Significance as a predictor of direct response to interferon. J Hepatol 26, 6 - 13 (1997)
16. Kanai K, Kako M and Okamoto H: HCV genotypes in chronic hepatitis C and response to interferon. Lancet 339, 1543 (1992)
17. Mizukoshi E, Kaneko S, Yanagi M, Ohno H, Kaji K, Terasaki S, Shimoda A, Matsushita E and Kobayashi K: Expression of interferon alpha/beta receptor in the liver of chronic hepatitis C patients. J Med Virol 56, 217 - 223 (1998)
18. Yatsuhashi H, Fujino T, Matsumoto T, Inoue O, Koga M and Yano M: Immunohistochemical analysis of hepatic interferon alpha-beta receptor level: Relationship between receptor expression and response to interferon therapy in patients with chronic hepatitis C. J Hepatol 30, 995 - 1003 (1999)
19. Naber D, Wirz-Justice A and Kafka MS: Circadian rhythm in rat brain opiate receptor. Neurosci Lett 21, 45 - 50 (1981)
20. Kavaliers M and Hirst M: Daily rhythms of analgesia in mice: Effects of age and photoperiod. Brain Res 279, 387 - 393 (1983)
21. Fraser J, Nadeau J, Robertson D and Wood, AJJ: Regulation of human leukocyte β-receptors by endogeneous catecholamies: Relationship of leukocyte β-receptor density to the cardiac sensitivity to isoproterenol. J Clin Invest 67, 1777-1784 (1981)
22. Zhou HH, Silberstein DJ, Koshakji RP and Wood AJJ: Inter-individual differences in β-receptor density contribute to variability in response to β-adrenoceptor antagonists. Clin Pharmacol Ther 45, 587-592 (1989)
23. Sokawa Y, Kitano Y, Shimada M, Okumura M, Sokawa J, Ueda K, Hamada K and Takeda K: Physiological expression of the 2′-5′ oligoadenylate synthetase gene in mouse intestine. J Interferon Res 14, 121-127 (1994)
24. Briese E, Hui-Wan H and Parada MA: Stress hyperthermia in mice. J Therm Biol 16, 333-336 (1991)
25. Kushnaryov VM, MacDonald HS, Sedmak JJ and Grossberg SE: Murine interferon-β receptor-mediated endocytosis and nuclear membrane binding. Proc Natl Acad Sci USA 82, 3281-3285 (1985)
26. Scatchard G: The attraction of protein for small molecules and ions. Ann NY Acad Sci 51, 660-672 (1949)
27. Lengyel P: Biochemistry of interferons and their actions. Annu Rev Biochem 51, 251-282 (1982)
28. Diaz-Guerra M, Rivas C and Esteban M: Inducible expression of the 2-5 A synthetase/RNase L system results in inhibition of vaccinia virus replication. Virology 227, 220-228 (1997)
29. Kumar R, Choubey D, Lengyel P and Sen GC: Studies on the role of the 2′-5′-oligoadenylate synthetase - RNase L pathway in beta interferon-mediated inhibition of encephalomyocarditis virus replication. J Virol 62, 3175-3181 (1988)
30. Zoon KC and Arnheiter H: Studies of the interferon receptors. Pharmacol Ther 24, 259-278 (1984)
31. Hwang SY, Hertzog PJ, Holland KA, Sumarsono SH, Tymms MJ, Hamilton JA, Whitty G, Bertoncello I and Kola I: A null mutation in the gene encoding a type I interferon receptor component eliminates antiproliferative and antiviral responses to interferons α and β and alters macrophage responses. Proc Natl Acad Sci USA 92, 11284-11288 (1995)
32. Fukuda R, Ishimura N, Kushiyama Y, Moriyama N, Ishihara S, Nagasawa S, Miyake T, Niigaki M, Satoh S, Sakai S, Akagi S, Watanabe M and Fukumoto S: Effectiveness of interferon-alpha therapy in chronic hepatitis C is associated with the amount of interferon-alpha receptor mRNA in the liver. J Hepatol 26, 455-461 (1997)
33. Davis ME, Akera T and Brody TM: Reduction of opiate binding to brain stem slices associated with the development of tolerance to morphine in rats. J Pharmacol Exp Ther 211, 112-119 (1979)
34. Nakashima T, Murakami T, Murai Y, Hori T, Miyata S and Kiyohara T: Naloxone suppresses the rising phase of fever induced by interferon-α. Brain Res Bull 37, 61-66 (1995)
35. Cao C, Matsumura K, Yamagata K and Watanabe Y: Endothelial cells of the rat brain vasculature express cyclooxygenase-2 mRNA in response to systemic interleukin-1β: A possible site of prostaglandin synthesis responsible for fever. Brain Res 733, 263-272 (1996)
36. Masferrer JL, Reddy ST, Zweifel BS, Seibert K, Needleman P, Gilbert RS and Herschman HR: In vivo glucocorticoids regulate cyclooxygenase-2 but not cyclooxygenase-1 in peritoneal macrophages. J Pharmacol Exp Ther 270, 1340-1344 (1994)
37. Yucel-Lindberg T, Ahola H, Nilsson S, Carlstedt-Duke J and Modeer T: Interleukin-1 beta induces expression of cyclooxygenase-2 mRNA in human gingival fibroblasts. Inflammation 19, 549-560 (1995)
38. 2α in the cerebrospinal fluid of anesthetized rats. Biochem Biophys Res Commun 213, 625-629 (1995)
39. Wills RJ: Clinical pharmacokinetics of interferons. Clin Pharmacokinet 19, 390-399 (1990)
40. 125I-interferon alpha by isolated perfused rabbit kidney and liver. J Lab Clin Med 101, 857-863 (1983)
41. Kuwabara T, Kato Y, Kobayashi S, Suzuki H and Sugiyama Y: Non-linear pharmacokinetics of a recombinant human granulocycte colony-stimulating factor derivative (nartograstim): Species differences among rats, monkeys and humans. J Pharmacol Exp Ther 271, 1535-1543 (1994)